Alcista Markets
Long only, deep value, growth, bonds

Acadia Pharmaceuticals Pipeline Set To Assist Aging Population

ACADIA Pharmaceuticals (NASDAQ:ACAD) is an undervalued small-cap stock that is developing advanced technology related to two common ailments that cause psychosis in the elderly, Alzheimer's and Parkinson's. Additionally, the company is using the same platform to develop a treatment for schizophrenia. Longer term projects include treatments for chronic pain and glaucoma and broader treatments for Parkinson's disease. Based on market and company research a price target of $25 for sometime between July 2014 and December 2014 is a realistic and achievable goal for the stock.

THE AGING POPULATION DRIVES A GROWING MARKET

There is no way around the fact that in major industrialized nations the population is aging and afflictions and diseases that affect this demographic are becoming...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details